podcast
details
.com
Print
Share
Look for any podcast host, guest or anyone
Search
Showing episodes and shows of
Insilico Terminal
Shows
AX Case Study Podcast
Insilico의 에이전트 기반 실험실 자율화
1. 왜 이 사례인가Insilico Medicine은 홍콩 증권거래소에 상장된(HKEX: 3696) 신약 개발 기업입니다. 이 회사는 스스로를 “임상 단계의 생성형 AI 기반 신약 개발 기업”으로 소개합니다. Longevity.Technology에 따르면 이 회사는 2014년에 설립되었으며, 홍콩 상장은 조달 금액 기준으로 2025년 홍콩 최대 규모의 바이오텍 IPO였습니다. 회사 소개 페이지에서 Insilico는 자사의 Pharma.AI 플랫폼을 기반으로 구축된 “엔드투엔드 생성형 AI 기반 바이오텍 기업”이라고 밝히고 있습니다. 이번에 소개하는 변화 이전부터 AI는 이미 회사의 일부였습니다. 보도자료에서도 표적 발굴 플랫폼인 PandaOmics와 자동화 실험실인 LifeStar2를 새로운 계층이 연결하는 기존 시스템으로 제시합니다.2026-05-06, Insilico는 “차세대 지능형 실험실 운영체제”라고 부르는 LabClaw를 발표했습니다. 보도자료 제목은 이번 변화를 “자동화에서 자율화로(from Automation to Autonomy)” 나아가는 과정으로 규정합니다. 실험실 로봇은 이미 도입되어 있었습니다. 달라진 점은 실험을 계획하고, 스테이션 간 작업을 조율하며, 사후 데이터를 처리하는 주체입니다. 보도자료에 따르면 이러한 업무가 사람에서 AI 에이전트 그룹으로 넘어가고, 연구자는 정해진 체크포인트에서만 개입합니다.이 사례가 주목받는 이유는 세 가지입니다. 첫째, 보도자료가 회사의 표현을 빌려 이전 상태를 명확히 기술하기 때문입니다. 사전 프로그래밍된 경직된 워크플로, AI 모델로 환류되지 않던 데이터, 실험실 스테이션 전반에 걸쳐 다단계 실험을 수작업으로 조율하던 인력 등이 이에 해당합니다. 둘째, 에이전트의 역할을 이름별로 명시하고 실제 실행 사례를 통해 연구자가 여전히 결정권을 행사하는 지점을 보여줍니다. 셋째, 웨트랩에서 도출된 결과가 표적 발굴 플랫폼으로 다시 공급되어 다음 예측 모델을 갱신한다는 점입니다.보도자료는 LabClaw를 “경량 Agent-Guard 구조를 기반으로 구축된 제약 업계 최초의 실험실 자율화 시스템”이라고 지칭합니다. 이는 회사 측 주장이며, 독립적인 기관의 검증을 거친 평가는 아닙니다. 아래에 기술된 LabClaw 관련 설명은 모두 Insilico의 발표 내용에 근거한 것이며, 외부에서 검증된 바는 없습니다.2. Problem보도자료는 기존 실험실 자동화가 이미 달성한 성과부터 짚고 넘어갑니다. 액체 핸들링 워크스테이션, 고처리량 스크리닝 플랫폼, 자동화 세포 배양 시스템 덕분에 수작업 대비 “실험 처리량이 획기적으로 증가”했고 체계적 오류가 줄었다고 설명합니다. 보도자료가 지적하는 문제는 그러한 장비 주변에 여전히 수작업으로 남아 있던 영역입니다. 보도자료는 “자동화에서 진정한 자율화로 나아가는 과정”에서 마주하는 세 가지 병목을 다음과 같이 열거합니다.“워크플로의 경직성: 사전 프로그래밍된 워크플로는 동적 변수에 유연하게 대응하기 어렵습니다. 중간 단계에서 오류가 발생하거나 QC 이상 징후가 나타나면 시스템은 사람의 개입을 필요로 했습니다.”“데이터 사일로: 자동 해석 및 폐쇄 루프 피드백 경로가 없으면, 장비에서 쏟아져 나오는 대량의 데이터가 상위 단계의 AI 생성 추론이나 하위 단계의 통계 분석과 연결되지 못해 실시간 데이터 활용과 가치 실현이 제한됩니다.”“높은 조율 비용: 서로 다른 기능 구역에 걸친 다단계 실험을 여전히 수작업으로 조율하고 추적해야 하므로, 연구 외적인 업무가 과도하게 발생해 생산성 병목이 생깁니다.”보도자료는 이를 자사 실험실에 국한된 진단이 아니라 업계 전반의 병목으로 제시합니다. 다만 사례 연구에서는 Insilico 연구진이 표적을 선정하기 전에 일하던 이전 방식을 “방대한 문헌을 검토하고 근거를 수작업으로 정리하던 비효율적인 기존 방식”으로 묘사하고 있습니다.종합하면 도입 전 상태는 다음과 같습니다. 연구자들은 문헌을 직접 읽고 후보 표적에 대한 근거를 수작업으로 모았습니다. 실험은 고정된 사전 프로그래밍 워크플로에 따라 진행되었습니다. 특정 단계에서 실패가 발생하거나 품질 검사상 이상이 보이면 사람이 개입해야 했습니다. 실험실의 분리된 스테이션 전반에 걸친 작업 일정 수립과 추적도 사람이 맡았습니다. 장비에서 나온 데이터는 실험을 애초에 제안했던 AI 모델로 자동 피드백되는 경로가 없었습니다.Insilico Medicine의 IT 총괄 디렉터인 Lin Sha는 과학자들의 부담을 덜어주고자 했던 영역을 다음과 같이 설명합니다.“LabClaw의 핵심적인 의의는 과학자들이 집중하는 대상을 재정의하는 데 있습니다. 시간 소모적인 표준 작업과 번거로운 일정 조율을 대신 맡아줌으로써, LabClaw는 지치지 않는 연구 코파일럿 역할을 수행합니다.”확인된 사실: 기존 실험실 자동화(액체 핸들링, 고처리량 스크리닝, 자동화 세포 배양)가 배경으로 언급됨. 회사 측이 밝힌 세 가지 병목(단계 실패나 QC 이상 시 수작업 개입이 필요한 워크플로 경직성, 장비 출력값과 AI 추론 간의 데이터 사일로, 기능 구역 전반의 수작업 조율 및 추적). 회사 측이 비효율적이라고 설명한 수작업 문헌 검토 및 근거 정리 방식의 과거 표적 연구. Lin Sha의 발언.3. Solution3.1 LabClaw의 기반 계층LabClaw는 실험실 하드웨어를 대체하지 않습니다. 보도자료에 따르면 이 시스템은 “Insilico의 완전 자동화 실험실인 LifeStar2를 보완하도록 특별히 설계”되었습니다. LabClaw는 기존의 네 가지 계층을 연결합니다.* Insilico의 자체 AI 표적 발굴 플랫폼인 PandaOmics* 자동화 실험실 하드웨어: 세포 배양, 고처리량 스크리닝, NGS(차세대 염기서열 분석) 등을 포함하며 “수십 대의 장비에 걸쳐 있는” LifeStar2 내 6개 기능 구역 및 구역 간 자재를 운반하는 AGV(무인 운반차)* LIMS(실험실 정보 관리 시스템)* 데이터 분석 파이프라인보도자료는 이러한 구성을 “AI의 사고, 자동화된 실행, 인간의 감독으로 구성된 새로운 3대 축의 실험 패러다임”이라고 설명합니다.3.2 정해진 역할을 수행하는 다섯 에이전트보도자료에 따르면 LabClaw는 5개의 협업 AI 에이전트와 28개의 전문 스킬 모듈로 구성됩니다. 에이전트는 역할별로 다음과 같이 명명되었습니다.* Experiment Coordinator* Orchestration Expert* Science Analyst* QC Inspector* Data Specialist보도자료에서는 이 중 세 에이전트의 실제 업무를 설명합니다. Science Analyst는 PandaOmics 및 기타 지식 베이스를 검색하여 근거와 함께 표적을 제안합니다. Experiment Coordinator는 선정된 표적을 실험실 절차로 변환하여 실행합니다. QC Inspector는 전 과정에서 “환경 매개변수와 세포 상태”를 모니터링합니다. 보도자료에는 Orchestration Expert와 Data Specialist에 대해 이름 외의 구체적인 설명이 없으며, 에이전트들이 어떤 모델을 사용하는지도 명시되어 있지 않습니다.3.3 연구자의 승인 지점보도자료는 이 설계를 “Agent-Guard 구조”라고 부릅니다. 에이전트는 제한된 범위 내에서 자율적으로 행동하지만, 특
2026-11-14
17 min
Insilico Terminal Podcast
Knot on front-running FTX's leveraged token rebalances
Knot, one of the engineers behind Insilico Terminal, joins Sokio to talk about how a degree in jazz performance and coding audio plugins turned into a career building trading systems. A TradFi systems trader told him "TA is astrology for men", so he went into arbitrage instead, running fat-finger and new-listing loops across exchanges when crypto still felt like easy mode. We get into the FTX leveraged-token trade he ran for about a year and a half: working out how much each daily rebalance had to buy or sell against the market's open interest, scraping FTX's token pages into E...
2026-10-29
1h 19
BiotechTV - News
After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress
He describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus, the logevity component Insilico has built into its IPF trials, and what other programs and targets he calls out.
2026-10-06
27 min
AI Brief
EP 623 : OpenAI’s AI Intern Breakthrough, Insilico’s Anti‑Aging Drug & US Voter AI Fear
Ever wondered how far behind the rest of the world you are when OpenAI’s internal AI agents start out‑producing human researchers? In this episode we peel back the curtain on OpenAI’s newly published research intern report, revealing that coding agents now log 3.1 workdays for every human day, that 80 % of researchers juggle four or more agents simultaneously, and that token spending has exploded to over $600 per day per researcher. We discuss why this “internal use advantage” could widen the gap between frontier labs and every other AI team.Next, we shift to biotech. Insilico Medicine’s AI‑designed molecul...
2026-09-09
15 min
AI Fire Daily
🎙️ EP 351: OpenAI to Navier–Stokes Problem & Insilico AI Drug Shows Anti-Aging Signal
OpenAI announced that an internal AI system deployed a swarm of roughly 10,000 concurrent agents over 88 hours to produce a formal Lean-verified proof addressing the Navier–Stokes Millennium Prize Problem. Meanwhile, a study published in Nature Biotechnology revealed that Insilico Medicine's AI-designed drug rentosertib significantly reduced biological age markers across six independent proteomic clocks in a Phase 2a trial.We’ll talk about:A 10,000-agent AI swarm utilizing 130B output tokens to generate a 165-page proof and Lean formalization of finite-time blowup in fluid dynamics.Phase 2a trial data showing an AI-designed idiopathic pulmonary fibrosis drug...
2026-09-09
13 min
名古屋ではたらく社長のITニュースポッドキャスト
Ep.1491 AI創薬がもたらす“若返り”の衝撃──Insilico Medicineの新薬「Rentosertib」が示す未来(2026年9月9日配信)
タイトルAI創薬がもたらす“若返り”の衝撃──Insilico Medicineの新薬「Rentosertib」が示す未来このエピソードで登場するキーワードを説明します。Insilico Medicine: 香港や米国に拠点を置き、AIを活用した創薬(AI Drug Discovery)を牽引するバイオテクノロジー企業。AIによる標的の発見から分子設計までをエンドツーエンドで手掛ける。Rentosertib(レントセルチブ): Insilico Medicineが自社のAIプラットフォームを活用して開発した、特発性肺線維症(IPF)の治療薬候補。老化と線維化に関与するTNIKというタンパク質を阻害するよう設計されている。老化時計(Proteomic aging clocks): 血液中のタンパク質プロファイルなどの生体データから、人体の細胞レベルでの損傷度合いや「生物学的年齢」を高い精度で予測するAIモデルの総称。それでは解説に入ります。2026年9月7日から8日にかけて、AI創薬スタートアップのInsilico Medicineが、AIによって設計された新薬候補「Rentosertib」の第2a相臨床試験において、人間の生物学的年齢を逆転させる可能性を示すデータを発表しました。この研究成果は権威ある英科学誌『Nature Biotechnology』に掲載され、製薬およびテクノロジー業界の双方から強い関心を集めています。Rentosertibは元来、肺が硬くなり呼吸機能が低下する難病である特発性肺線維症(IPF)の治療を目的に開発された低分子化合物です。Insilico Medicineは自社の標的発見AI「PandaOmics」と生成AIを用いた分子設計プラットフォーム「Chemistry42」を活用し、通常であれば数年を要する候補物質の特定を約18カ月という驚異的なスピードで完了させました。今回の発表の核心は、IPF患者42人を対象とした臨床試験の血液サンプルを、ハーバード大学やオックスフォード大学などが独立して開発した6つの異なる「老化時計」モデルで分析した点にあります。その結果、これら6つすべてのモデルにおいて、Rentosertibを投与された患者の生物学的年齢が一貫して低下していることが確認されました。特定の投与群においては、わずか4週間で生物学的年齢が平均して3年から4年、一部の指標では最大6年分若返るという結果が示されています。このニュースがビジネスや投資の観点で極めて重要なのは、AI創薬が単なる「研究開発コストの削減」にとどまらず、これまで人類が到達できなかった「老化の制御」という未踏の市場を切り拓く実証データになり得るからです。現在、世界のAI創薬市場ではGoogle傘下のIsomorphic LabsやRecursion、さらには設立間もない段階で38億ドルの評価額をつけたChai Discoveryなど、気鋭のスタートアップが激しい競争を繰り広げています。しかし、AIで見出した標的に対して自社で新薬を設計し、臨床試験の後期段階まで一貫して進め、さらに「若返り」という副次的かつ破壊的な効果を人体で実証しつつある点で、Insilico Medicineは競合から一歩抜け出した形となります。同社の試算によれば、全人類の寿命を健康な状態でわずか3年延ばすだけでも、世界規模で数兆ドル規模の生産性向上と膨大な医療コストの削減に直結するとされています。現在の規制環境において「老化防止」そのものを疾患として当局から承認を得るハードルは依然として高いものの、他の適応症でRentosertibが承認されれば、将来的にアンチエイジング目的での巨大な市場形成が見込まれます。既存の巨大製薬企業がAIスタートアップへの投資や大型提携を加速させる中、AIがデザインした分子が私たちの「寿命」という究極の指標をいかに書き換えていくのか、今後の治験データと業界再編の動向から目が離せません。今回のエピソードは以上で終了です。また次回お会いしましょう。
2026-09-09
04 min
The Market Edge
Tech Giants Shift: Samsung, Intel, Insilico in 2026
Explore strategic financial maneuvers and technological advancements in the tech and pharmaceutical sectors. Delve into Samsung's buyback, Intel's price hike, and Insilico's AI-driven drug discoveries, impacting market dynamics and future strategies.📥 Connect with The Market EdgeEnjoyed this episode? Make sure to follow the channel and turn on notifications so you never miss a market breakdown.Spreaker: The Market Edge LinkBusiness Inquiries: golden.wave.soundworks@gmail.com📈 About The Market EdgeThe Market Edge strips away the hype to deliver sharp, data-driven insights, macroeconomic analysis, and actionable strategies. Whether you are tr...
2026-09-08
18 min
Stock Movers
Samsung Gains, Asia PC Drops, Insilico Jumps
Today's biggest winners and losers in the stock market.On this episode of Stock Movers:- Samsung's anticipated equity buyback is raising investor expectations that the Korean giant will buy up non‑voting preferred shares, narrowing a steep discount and setting an example for others. - Asia PC maker shares drop after a report that Intel plans to raise personal computer CPU prices by another 10% as early as next month.- An experimental lung disease drug developed using artificial intelligence showed promise in reversing biological signs of ageing, pointing to broader potential use of the tr...
2026-09-08
04 min
The State of Tech Die deutsche Ausgabe
KI-Medikament: Insilico zeigt Verjüngungs-Signal
The State of Tech DE vom Dienstag, 8. September 2026 KI-entwickeltes Lungenmedikament von Insilico lässt Patienten biologisch jünger aussehen Malaysia wählt Huawei-Chips für nationales KI-Projekt und trotzt US-Exportwarnungen Nvidia-Schlupfloch bei Chip-Exporten überschattet erstes US-China-KI-Gipfeltreffen Quantencomputer-Anbieter IonQ übernimmt Chipfabrik SkyWater Technology CryptPad: Ende-zu-Ende-verschlüsselte europäische Büro-Suite im Browser Magic Earth Pro: Offline-Navigation durch ganz Europa ohne Tracking und Abo
2026-09-08
15 min
The State of Tech
AI-longmedicijn verjongt patiënten biologisch: Insilico Medicine
The State of Tech van dinsdag 8 september 2026 Door AI ontworpen longmedicijn van Insilico laat patiënten biologisch jonger lijken Maleisië kiest Huawei-AI-chips voor nationaal project, ondanks Amerikaanse exportwaarschuwingen Gemeld lek in Nvidia-exportcontroles overschaduwt eerste AI-top tussen Washington en Peking IonQ zet quantumsector op scherp met overname van chipfabrikant SkyWater CryptPad: het versleutelde Europese kantoorpakket dat je documenten echt privé houdt Magic Earth Pro: offline navigatie voor heel Europa zonder tracking of abonnement
2026-09-08
15 min
The State of Tech — The European Edition
Insilico AI drug reverses ageing + Malaysia picks Huawei
The State of Tech, The European Edition of Tuesday 8 September 2026 Insilico Medicine's AI-designed lung drug shows signs of reversing biological age across six independent clocks Malaysia picks Huawei chips over American alternatives for its two-billion-ringgit sovereign AI project A Nvidia chip export loophole casts a shadow over the first US-China AI summit of Trump's second term IonQ holds investor day with its SkyWater semiconductor acquisition at the centre of its quantum supply chain strategy CryptPad: the free, open-source, end-to-end encrypted European office suite Magic Earth Pro: full offline navigation across Europe with no tracking and no subscription
2026-09-08
14 min
Insilico Terminal Podcast
How Trader Morin built a repeatable edge after 18 months at breakeven
Trader Morin turned more than 18 months at breakeven into a repeatable trading process built around ranges, mean reversion, order flow and strict risk management. He explains how he plans trades days in advance, builds price-action and footprint execution playbooks, sizes positions using confluence, and distinguishes reaccumulation from redistribution. We also discuss surviving the unprofitable years, handling FOMO, reviewing trading data, using leverage responsibly and why Morin deliberately reduces risk after a major winner.00:00 First blow-up and playing the long game 08:05 Why Morin focused on BTC and ETH 18:07 Building conviction, trade plans and playbooks
2026-09-03
1h 19
Insilico Terminal Podcast
Cryptopia, FTX and the hunt for overlooked edge - Beniduboss
Benoit Dubosson, better known as Beni the Boss, joins the Insilico Terminal Podcast for his first interview about crypto. He explains how he built a trading career around markets other people ignored—from Cryptopia arbitrage and onchain deposit signals to FTX funding trades, the Luna collapse, TradeOgre market making, and strange dislocations across CFD brokers and fintech apps. Beni also talks about counterparty risk, the mental cost of trading your own money, why he eventually left crypto, the role of luck in success, and why beginners should spend far more time researching than trading.00:00 From online poker to...
2026-08-27
1h 23
Insilico Terminal Podcast
Trading Everything on Hyperliquid | Perps.fun Co-Founder Parker
Parker, co-founder of perps.fun, joins the Insilico Terminal Podcast to discuss building the first HIP-3 launchpad and opening Hyperliquid market creation to teams outside the existing deployer structure. We cover why perps.fun pivoted from building a trading terminal, how new markets are vetted, fee sharing and market ownership, exotic and long-tail perps, sourcing liquidity, oracle and funding design, the Kinetiq partnership, and why permissionless perp creation comes with serious risks. We also get into the wider Hyperliquid ecosystem: HIP-3 market concentration, HIP-4, regulation, institutional adoption, Trade XYZ, competition between DEXs, and the long-term vision of being able to...
2026-08-20
46 min
Inside AsembleAI: DeepTech, AI & Science
EP 53: Ai4 Podcast - Revolutionizing Healthcare: AI in Drug Discovery | Alex Zhavoronkov, Insilico Medicine
This episode was recorded live from the Ai4 conference podcast pavilion, Sam sat down with Alex Zhavoronkov, Founder & CEO of Insilico Medicine, about what it actually takes to turn AI-generated molecules into approved drugs.What's Covered:From Laughed-Out-of-the-Room to 33 Candidates — Alex pitched generative AI for drug design in 2015 and got dismissed. Today: 33 developmental candidates in six years, zero failed toxicity studies, and deals with Eli Lilly, Takeda, Servier, and SK Bio at a pace of nearly one per month.The Real Bottleneck — "It's not about a story. Many people in our field love to t...
2026-08-17
40 min
Insilico Terminal Podcast
HypeTrader on million-dollar drawdowns and rebuilding his edge
HypeTrader, also known as @MomentumKevin, joins Sokio to talk about the wins, losses and mindset shifts behind his journey as a high-volume Hyperliquid trader. Kevin traces his path from buying the 2013 Bitcoin top and trading the 2017 altcoin cycle to BitMEX liquidations, NFTs and eventually HYPE. He speaks openly about million-dollar drawdowns, losing most of two years of trading P&L, and why he is now sizing down and focusing on more repeatable intraday trades. They also discuss trading stock perps on Hyperliquid, sentiment and order flow, execution costs, competing perp DEXs, the future of HYPE and whether Hyperliquid can be...
2026-08-13
51 min
Insilico Terminal Podcast
StonkTrump on options flow, crowded trades and buying market fear
Stonk Trump joins the Insilico Terminal Podcast to explain how he uses institutional positioning, options flow and technical analysis to find swing trades across equities and options. We discuss why the worst headlines often arrive near market bottoms, how he structures longer-dated calls and takes profit, and why good earnings cannot save a trade that everyone already owns. He also breaks down the semiconductor unwind, what crypto traders can bring to TradFi, and why he is waiting for better Bitcoin opportunities into the fall.00:00 From crypto to options 06:30 Meme stocks, silver and early trading lessons
2026-08-06
59 min
Insilico Terminal Podcast
Felix Jauvin - Macro, AI & why crypto looks underowned
Felix Jauvin, Head of Content at Blockworks and host of Forward Guidance, joins the Insilico Terminal Podcast to talk macro, crypto, AI and the current market setup. We get into why macro has become harder to apply to Bitcoin, which economic signals actually matter for traders, how Felix structures his own portfolio, the risks around Saylor and Strategy, and why he thinks much of the easy money in the AI trade may already have been made. Felix also explains why he’s becoming more constructive on crypto again, how the CLARITY Act could become an important catalyst, what stablecoins actu...
2026-07-30
1h 00
Insilico Terminal Podcast
Hyperliquid's Next Chapter - Omnia on Kinetiq, HIP-3 & the House of All Finance
Omnia joins the Insilico Terminal Podcast to discuss his path from NFT market making and crypto investing to building Kinetiq, the largest protocol on Hyperliquid. We cover what convinced him to bet on Hyperliquid early, how HyperBFT and HyperEVM work, what K-HYPE offers holders, and how Markets by Kinetiq is approaching HIP-3 markets. We also discuss the challenges of building inside the Hyperliquid ecosystem, the future of perp DEX competition, crypto tribalism, institutional adoption, and what it would take for Hyperliquid to become the house of all finance.00:00 NFT Market Making & Omnia’s Crypto Origin 07:05 From...
2026-07-23
1h 00
DX Today | No-Hype Podcast & News About AI & DX
AI Designed Drugs Face Their Reckoning: Isomorphic Labs, Insilico's Phase 3, and Medicine's Make or Break Year - July 20, 2026
AI Designed Drugs Face Their Reckoning: Isomorphic Labs, Insilico's Phase 3, and Medicine's Make or Break Year Two milestones just turned AI drug discovery from promise into a real world test. Isomorphic Labs, the Google DeepMind spinoff built on the AlphaFold lineage, is moving its first AI designed molecules into human oncology trials, while Insilico Medicine has pushed rentosertib, an AI discovered treatment for the lung disease idiopathic pulmonary fibrosis, into a pivotal Phase 3 study. With roughly 60 billion dollars invested since 2019, around 200 AI originated programs in human trials, and still zero FDA approvals, Chris and Laura dig into...
2026-07-20
13 min
Touching Base
Parkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics
Promise hits Parkinson’s disease therapy, as a Phase I/II clinical study has demonstrated the feasibility of transplanting stem-cell-derived dopamine progenitor cells into the brain. In preclinical research, a new platform uses the brain’s fluid transport pathways to effectively deliver AAVs to therapeutic targets in mice. We’ll also cover the accelerating infrastructure moment for AI-driven drug discovery, with billion-dollar investments flowing into end-to-end platforms driven by models and compute, rather than single drug assets. In business, Insilico’s revenue leaps as the company’s AI-developed lead candidate moves to Phase III, while Vertex acquires Crinetics for $10 billion. ...
2026-07-17
32 min
Insilico Terminal Podcast
Block Scholes: Crypto Derivatives, Prediction Markets, and Why Institutions Are Still Here
Andrew from Block Scholes joins the Insilico Terminal Podcast to talk about crypto derivatives, options data, volatility surfaces, prediction markets, AI market makers, and why institutions are still building in crypto despite the bear market. We covered what Block Scholes does, how their data is used by exchanges, market makers, banks, and DeFi teams, why prediction markets are basically retail-friendly options, how volatility surfaces help price markets that don’t exist yet, and what changes when AI tooling makes it easier for anyone to build trading bots. We also talked about the current state of crypto, why headline prices don’...
2026-07-16
00 min
Insilico Terminal Podcast
HackermanAce: Finding Edges with Ichimoku, Options, and On-Chain Trading
HackermanAce joins the Insilico Terminal Podcast to talk about Ichimoku trading, finding a real system, crypto options, volatility, hedging, on-chain venues, LPing memecoins, Solana, Hyperliquid, and where the next cycle could come from. We covered how Ace went from early crypto mistakes to full-time trading, why he built his style around Ichimoku Cloud setups, why day trading burns people out, how crypto traders can start learning options, when options make more sense than perps, why hedging is underrated, and how LPing memecoins can work almost like an options strategy.00:00 Ace’s Crypto Origin Story 06:31 Why Day...
2026-07-09
54 min
Touching Base
Merck and Insilico Make Deals, Claude Science’s Debut, Vaccines for Neglected Diseases
More big biotech deals on the docket this week. First, Merck KGaA is buying Bio-Techne for $11.3 billion to expand its presence in high-growth life science markets. We dive into the details of this deal and then turn our attention to a $2.5 million collaboration to use artificial intelligence to find drug candidates for neuroimmune disorders. That deal involves Insilico Medicine and SK Biopharmaceuticals. Still on the theme of AI, we discuss Anthropic’s Claude Science, the latest entrant to the growing ecosystem of tech platforms specialized for biology, and a set of models for antibiotic design and vaccine target prediction. La...
2026-07-02
35 min
Insilico Terminal Podcast
Why options are easier than you think - Thalex founder Hendrik Ghys on volatility and delta hedging
Hendrik Ghys, Co-Founder & CEO of Thalex, joins the Insilico Terminal Podcast to talk about crypto options, volatility trading, market makers, delta hedging, and why options are easier than most traders think. We cover how Thalex is building a crypto options exchange, why options are harder to bring on-chain than perps, how MOVE-style contracts work, what market makers actually do when they hedge, and how traders can think about perps vs options. The episode also covers selling volatility, delta hedging straddles, OPEX, gamma, call spreads, longer-dated options, and why many retail traders might be making trading harder than it needs to...
2026-07-02
1h 04
Insilico Terminal Podcast
No Brains, All Balls, and Why Execution Beats Analysis with EmptyBrainTrader
EmptyBrainTrader joins the Insilico Terminal Podcast to talk about crypto trading, execution, mean reversion, and the psychology of actually clicking the button. We covered his early mistakes buying XRP and Zcash, blowing up in 2022, studying DOM and auction market theory, building a mean reversion style, dealing with FOMO and revenge trading, and why execution often matters more than perfect analysis. We also talked about the current crypto market, Saylor fear, BTC downside risk, HYPE, Hyperliquid, perp DEXs, Extended, Variational, prediction markets, and why traders should focus on not losing big.00:00 No Brains, All Balls and why execution ma...
2026-06-25
58 min
MDBros|Paradigm Shifts in Healthcare
搞顯示卡的人跑去製藥|Eroom 定律的第一道裂縫,Insilico 與 AI 製藥未來二十年的結構轉移
製藥是門越做越貴的生意,Eroom 定律下每款新藥平均得燒十多年、26 億美元,而最大的成本其實是失敗;Insilico Medicine(英矽智能)想用 AI 把賭錯這件事提早攤牌,靠 Pharma.AI 平台讓機器自己找病因、畫分子,做出針對特發性肺纖維化(IPF)的 rentosertib。2025 年它的第二期數據登上《Nature Medicine》、年底敲響港交所,成為全球最接近第一顆 AI 製藥頭銜的選手之一,但訊號雖亮,第三期才是真正的大考。 -- Hosting provided by SoundOn
2026-06-20
42 min
Insilico Terminal Podcast
CryptoGoon: Finding Edges in Broken Markets
CryptoGoon joins the Insilico Terminal Podcast to talk about leaving TradFi, discovering early DeFi, getting rugged, and finding real trading edges across crypto markets. We cover the difference between solo trading and working inside a trading firm, how simple arbs and broken on-chain mechanics turned into profitable trades, what market making actually looks like, and why new perp DEXs and prediction markets can still offer opportunities for traders willing to dig. He also shares his thoughts on Hyperliquid, HYPE, points farming, the current state of crypto, and why quant trading is often less about complex math and more about fi...
2026-06-18
59 min
Realities Remixed
RRSP02 The state of Life Sciences, pt 2 - How AI relates to human life and longevity with Dr. Alex Zhavoronkov, Insilico Medicine
Life sciences are at a critical inflection point, where scientific innovation, regulatory demands, and patient expectations converge with advances in data and artificial intelligence, positioning IT as a central driver of faster and more effective drug discovery and clinical development.This week, Dave and Rob continue with part 2 off the Life Sciences mini-series with Dr. Alex Zhavoronkov founder and CEO of Insilico Medicine to exploring how drug discovery and clinical development can become faster and more effective, and the role of AI in that process. TLDR00:40 – Introduction01:00 – Hang out: Kill Bill V...
2026-06-18
47 min
Insilico Terminal Podcast
Selling Vol, Market Making, and the Future of Crypto Options | Marty
Marty joins the Insilico Terminal Podcast to talk about his path from early Bitcoin and BitMEX to becoming a top perps and spot market maker on FTX, and later moving deeper into crypto options. We discuss why options market making is so different from perps, why retail still prefers simple up/down leverage, how structured products work, what went wrong with DeFi options, and why portfolio margin matters. Marty also shares his view on volatility selling, surviving major market stress events, the current state of Bitcoin and ETH, and why Hyperliquid has become one of the most important venues in...
2026-06-04
1h 04
Insilico Terminal Podcast
Most traders fool themselves with backtests - GoshawkTrades on systematic trading
In this episode, we’re joined by @GoshawkTrades, a systematic and algorithmic trader running 12+ live strategies across futures, equities, and crypto. We talk about how he got into trading, why he moved toward systematic strategies, what he got wrong early, and what his trading looks like today. We also cover where strategy ideas come from, how to test them properly, the most common backtesting mistakes, strategy decay, correlation across multiple algos, risk management, kill switches, quant vs discretionary trading, and how AI agents could change markets over the next few years.00:00 Getting into trading and moving from disc...
2026-05-28
1h 05
Alpha Casts - AI Market Intelligence
AI, Solar and Retail Ripples: Cognex Upgrade, Insilico’s Longevity AI and a Solar Showcase Drive Today’s Market Themes
$JPM — JPMorgan’s upgrade of Cognex (CGNX), an Insilico Medicine partnership to build an AI foundation model for longevity, and a Dinto Solar product showcase led headlines today. Retail distribution wins, payments integrations and leadership hires add sector-specific catalysts as traders parse volume swings in inverse small-cap ETF TZA.
2026-05-27
07 min
Insilico Terminal Podcast
Why Retail Gets Trapped - Skew on Order Flow, Altcoins, and Crypto Market Structure
Skew joins the Insilico Terminal Podcast to talk about how crypto markets have changed, why trading is more competitive now, and how he uses order flow, market structure, CVD, OI, funding, and sentiment to find trades. We covered his early Bitcoin story, learning to trade on BitMEX, the difference between speculation and real trading, how large players create traps in the market, how to find strong altcoins, and what he is watching in the current macro and crypto cycle.00:00 The story behind “52kskew” and finding Bitcoin early 09:07 Learning to trade on BitMEX and why price action...
2026-05-21
1h 05
Insilico Terminal Podcast
The joy of missing out - Jords on Hyperliquid, Solana, and making it in crypto
Jords joins the Insilico Terminal Podcast to talk about his path through crypto, from early trading mistakes and Solana NFTs to Hyperliquid, airdrops, logging off, and coming back when the market looked dead again.We talked about why he avoids perps, how he became early to Solana NFTs, what made Hyperliquid stand out before the airdrop, why he prefers buying depressed assets over chasing leverage, and how logging off changed his relationship with crypto.Also covered: missing Trump coin, the joy of missing out, buying when everyone thinks it’s over, BTC/HYPE positioning, crypto cy...
2026-05-14
1h 04
Insilico Terminal Podcast
StonXBT: Turning 3K Into 800K, Prop Trading, Risk Management & Macro
StonXBT joined the Insilico Terminal Podcast to talk about his path from early crypto, learning market profile and order flow, trading on a prop desk, and building a risk-first approach to markets. We covered scalping DOM and iceberg orders, why most traders skip real source material, how he thinks about position sizing and leverage, turning £3k into £800k, and why the biggest returns usually come from boring trend-following rather than constantly chasing trades. We also talked about Bitcoin, Hyperliquid, crypto losing its original identity, macro risk, oil, AI, the carry trade, and why markets can keep going up even when...
2026-05-07
1h 10
Insilico Terminal Podcast
Crypto isn't what it used to be - Krillin on markets, macro, and adapting as a trader
Krillin joins the Insilico Terminal Podcast to talk about getting into crypto in 2017, riding the altcoin euphoria, losing money through the bear market, and slowly turning that into a real trading process. We cover early altcoin trading, manual market making on IDEX, risk management, adapting across market conditions, why he moved more toward SPX and TradFi, how macro helped him sell the 2021 top, his thoughts on Hyperliquid, and why trading should be treated like a serious job - not a shortcut to getting rich.0:00 Intro & Krillin’s CT origin story 5:52 Getting into crypto in 2017 8:1...
2026-04-30
1h 01
Insilico Terminal Podcast
Rbit: Bitcoin Mining, Mt. Gox, Stat Arb & the Future of Crypto HFT
Rbit joins the Insilico Terminal Podcast to talk about his 15-year journey through crypto — from discovering Bitcoin on 4chan, mining BTC in 2011, losing funds on Mt. Gox, and trading the early BitMEX era, to building statistical arbitrage and HFT systems. We cover the 2017 ICO cycle, Bitcoin fork trades, why 2018 pushed him toward quantitative trading, what stat arb actually means, how HFT signals differ from longer-term strategies, why smaller venues can still offer major edge, and how crypto market structure is becoming more competitive as exchanges move closer to TradFi infrastructure.00:00 Getting into Bitcoin in 2010, mining, Mt. Gox, and...
2026-04-24
1h 06
Insilico Terminal Podcast
Why crypto feels harder now - Nexus on news trading, Hyperliquid, and market evolution
TheCryptoNexus joins the Insilico Terminal Podcast to talk about his path from blowing up trading accounts to making it back through news trading, how his style evolved from short-term scalping into more selective swing trading, and what he’s learned about risk, market structure, and surviving in crypto. The episode covers news trading, Hyperliquid, market evolution, meme coins, Bitcoin, and why making it in crypto feels harder now than it used to.Insilico Terminal Podcast Episode 31 - Nexus00:00 Intro, Nexus’ trading origin story from biotech stocks to crypto and short-term execution09:20 The Luna blow...
2026-04-16
1h 11
Colaberry AI Podcast
Eli Lilly and Insilico: A $2.75 Billion AI Pharmaceutical Alliance | 15th April 2026
Send us Fan MailHow Generative AI Is Transforming Drug Discovery and Global HealthcareKey Takeaways:💊 Eli Lilly is investing $2.75 billion in AI-driven drug development 🤖 Insilico Medicine uses generative AI to accelerate therapeutic discovery ⏱️ AI significantly reduces the time needed to identify and develop new drugs 🌍 The partnership expands global access to AI-created medications 🏢 Collaboration combines biotech innovation with large-scale pharma infrastructureSummaryIn this episode of the Colaberry AI Podcast, we explore a major milestone in the intersection of artificial intelligence and healthcare through the $2.75 billion pa...
2026-04-15
18 min
AI First Pod
AI Drug Discovery Breakthrough + Insilico Phase 2 Success & 31% Better Cancer Detection
Insilico Medicine announces its AI-designed anti-fibrotic drug has entered Phase 2 clinical trials in just 18 months — far faster than the industry average. We also cover: • Recursion Pharmaceuticals reporting 12 new clinical-stage drug candidates generated by its AI platform in the past year • Pfizer and Tempus partnering to use AI for matching cancer patients with personalized clinical trials • A new NEJM study showing AI-assisted diagnostic tools improved early cancer detection rates by 31% in routine screenings
2026-04-11
05 min
Insilico Terminal Podcast
What makes traders make it - Audy from Credo on edge, hiring, and crypto prop firms
Audy joins the Insilico Terminal Podcast to talk about his path from solo crypto trader to operations manager at Credo, how modern crypto prop firms actually work, and what separates traders who make it from those who don’t. The episode covers hiring, track records, discipline, confidence, portfolio construction, market regimes, and why working at a fund can be a much better path than trying to make it alone.Insilico Terminal Podcast Episode 30 - Audy, Head of Operations at Credo00:00 Intro, Audy’s background, Bybit competition breakthrough and joining Credo08:10 Inside the prop desk...
2026-04-09
1h 03
Insilico Terminal Podcast
Why trading is really a business - Worst Contrarian on arbitrage and edge
Worst Contrarian joins the Insilico Terminal Podcast to talk about his path into full-time trading, why he approaches markets like a business, and where he thinks real edge actually comes from. The episode covers arbitrage, exploiter mindset, inefficiencies in crypto and TradFi, trading psychology, expected value, and why most people are better off not trying to become traders in the first place.Insilico Terminal Podcast Episode 29 - Worst Contrarian 00:00 Intro, WC’s background, why he views trading as a business not speculation 04:07 First major arbitrage breakthrough, Binance AUD tether trade and going full-time ...
2026-04-02
1h 12
Vanguards of Healthcare by Bloomberg Intelligence
Inside Insilico Medicine’s AI Strategy and Lilly Breakthrough
“This deal [with Eli Lilly, announced on Sunday 29 March] is a combination of an asset licensing and collaboration. We’ve collaborated with Lilly in the past and they are actually one of the most active and expert users of our software,” says Alex Zhavoronkov, founder and co-CEO of Insilico Medicine. Zhavoronkov joins Bloomberg Intelligence pharmaceuticals analyst Sam Fazeli to explain how Insilico is using AI to compress drug-discovery timelines from years to months, pursue novel targets and compete with both big pharma and China’s fastest-moving biotech players. They also discuss the company’s rapid Lilly deal and why AI’s real...
2026-03-31
59 min
Tech News Daily
Lilly and Insilico Strike Big AI Drug Deal, Tinder Blends AI Romance, Master Power BI Performance, Tech Giants Bet on AI Infrastructure, and more...
(0:10): Eli Lilly and Insilico Strike $2.75B AI-Driven Drug Development Deal(2:20): Tinder Revamps with AI and Real-Life Dating to Captivate Gen Z(4:07): Master Power BI: Optimize Data Joins, Model Relationships, and Schema Designs for Performance(6:05): Tech Giants Shift Focus: AI Infrastructure Spending Over Workforce, Sparking Economic Transformation(8:09): Microscopic QR Code: Guinness World Record for Tiny, Durable Data Storage on CeramicTo subscribe visit https://www.brief.news.For more updates in your inbox each morning visit www.brief.news. Image credit: inkl
2026-03-30
10 min
AI News Daily
Lilly and Insilico Strike Big AI Drug Deal, LG Innotek Apps Sensing Revolution, Datamine Unveils AI MineScape 2026, Pro AI Group Bets $100M, and more...
(0:10): Eli Lilly and Insilico Strike $2.75B AI-Driven Drug Development Deal(2:25): LG Innotek and Applied Intuition Partner to Revolutionize Autonomous Driving Sensing Modules(4:12): Datamine Unveils AI-Driven MineScape 2026 for Real-Time Mining Optimization(6:41): Pro-AI Political Group to Pour $100M into 2026 Elections, Backing Trump's Deregulation Agenda(8:42): AI Stocks Face 2026 Volatility: Long-Term Strategy Focuses on Microsoft, Nvidia, Meta Amid Shifting ValuationsTo subscribe visit https://www.brief.news.For more updates in your inbox each morning visit www.brief.news. Image credit: KMJ
2026-03-30
11 min
Healthcare Daily Pulse
Insilico Medicine Enters Global R&D Collaboration with Eli Lilly for AI-Driven Drug Discovery
Intelligence Brief:Insilico Medicine Enters Global R&D Collaboration with Eli Lilly for AI-Driven Drug DiscoveryAI Maverick Intel to Acquire HEAL Access Canada Inc. for $5 Million and 20 Million SharesTrump Administration Unveils $50 Billion Rural Health Transformation Program to Combat Healthcare Crisis with AIRoche Launches cobas MPX-E Assaya New 4-in-1 Donor Screening Test**(SOUND of energetic, futuristic news intro music fading slightly into background)****ALEX:** Welcome back to Healthcare Daily Pulse, your rapid-fire download on the critical shifts in healthcare'. I’m Alex, your resident P&L hawk.**SAM:** And I’m Sam, charting the market's traj...
2026-03-30
15 min
The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes
Mar 29, 2026 | Lilly's $2.75B AI Drug Deal with Insilico; Oral Psoriasis Data Reshapes Derm at AAD 2026
Eli Lilly signs $2.75B biobucks deal with Insilico Medicinefor AI-discovered oral therapeutics. AAD 2026 brings 52-week ICOTYDE, zasocitinib Phase 3 psoriasis data, and Sanofi amlitelimab Q12W dosing in atopic dermatitis. Plus HI-PEITHO PE results from ACC and Merck's WINREVAIRCADENCE proof-of-concept.Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Eli Lilly, InsilicoMedicine, AI drug discovery, ICOTYDE, icotrokinra, zasocitinib, Takeda, Johnson Johnson, Sanofi, amlitelimab, sonelokimab, MoonLake, Boston Scientific, EKOS,HI-PEITHO, pulmonary embolism, WINREVAIR, sotatercept, Merck, Angelini Pharma,Recordati, CVC Capital Partners, AAD 2026...
2026-03-30
13 min
Insilico Terminal Podcast
Where the dumb flow lives - Liquidity Goblin on finding edge in crypto
Liquidity Goblin joins the Insilico Terminal Podcast to talk about his path from TradFi HFT into crypto, how he approaches DeFi, arbitrage, venue selection, and the kinds of inefficiencies smaller traders can still exploit. The episode covers market structure, manual vs systematic trading, risk management, points farming, meme coins, prediction markets, and where real edge still exists in crypto.Insilico Terminal Podcast Episode 28 - Liquidity Goblin00:00 Intro, Liquidity Goblin background and HFT → crypto transition 08:05 How HFT actually works: signals, arbitrage and cross-venue edges 16:31 Trading mindset: forecasts, horizons and avoiding thesis drift ...
2026-03-26
1h 14
Insilico Terminal Podcast
The cost of the trader life - Jim Talbot on burnout, discipline, and growth
Jim Talbot joins the Insilico Terminal Podcast to talk about his path from crypto trader to product manager, how trading shaped his market view, and why he found more meaning in building with a team. The episode covers burnout, market evolution, metals, high-timeframe trading, and the mindset shifts that come after the trader arc.Insilico Terminal Podcast Episode 27 - Jim00:00 Intro, Jim’s background, perma-bear arc and joining Insilico Terminal 08:05 Learning low timeframe trading, finding strategies, RSI divergence edge 16:31 Shift to higher timeframes, volatility changes and FTX/Alameda inefficiencies 25:06 2022 break...
2026-03-19
1h 02
Insilico Terminal Podcast
The trader behind the spaghetti charts - BTC Charlie on alt rotations and risk
In this episode, we’re joined by Bitcoin Charlie, a long-time crypto trader known for alt rotations and comparative “spaghetti” charts on CT. Charlie shares his journey from entering crypto in 2017, making and losing money in his first cycle, and returning more disciplined in the 2020–2021 bull market. We talk about the infamous missed SHIB fortune, lessons from fumbling huge gains, and how his trading style evolved around relative strength and altcoin rotations. The conversation explores cycle psychology, navigating bull-market mania, why most traders give profits back, and how Charlie approaches markets today after years of hard-earned experience.Insilico...
2026-03-12
1h 01
Insilico Terminal Podcast
How TraderMercury rebuilt after ego, liquidation, and bad habits
In this episode, Mercury shares his journey from early crypto curiosity to becoming a systematic trader focused on momentum, carry, and volatility strategies. We dive into the differences between discretionary and systematic trading, how he builds and tests models, and why many edges in crypto are really risk premia rather than pure alpha. Mercury explains infrastructure for running strategies across perp DEXs, volatility targeting, portfolio construction, and the realities of scaling capital. The conversation also touches on prediction markets, the role of AI in research, and how traders can survive in a market where edges constantly decay....
2026-03-05
1h 12
Insilico Terminal Podcast
How PonziTrader lost $800K in one night - and kept going
In this episode, PonziTrader shares his full journey - from buying Bitcoin to buy weed on the dark web to becoming a high-volume directional perp trader. He walks through spinning $2k into $50k in 2017, losing it all in 2018, printing during the COVID crash, and the brutal 2021 flash crash where he lost $800k in a single night. We dive deep into real vs fake moves, exchange flow dynamics, ETF-driven markets, perp DEX competition, Hyperliquid’s stickiness, and his advisory role with NADO. Beyond trading mechanics, the conversation explores risk-taking when young, rebuilding after wipeouts, the psychology of leverage, and why mo...
2026-02-26
56 min
Insilico Terminal Podcast
Why most retail edge isn't real - Pedma on quant trading and crypto
In this episode, Pedma shares his journey from bookkeeping and small-cap equities into fully systematic crypto trading. We dive deep into the difference between discretionary and quant approaches, why most retail trading is just momentum “seen through a potato,” and how real edge requires understanding why you’re getting paid for exposure. Pedma explains his long/short momentum models, carry strategies across perp DEXs, volatility targeting, and infrastructure for systematic execution. We also discuss alpha vs risk premium harvesting, prediction markets, perp DEX innovation, AI in trading, scaling capital, and the psychological impact of increasing size. The episode closes with p...
2026-02-19
59 min
Insilico Terminal Podcast
From indicators to real market structure - Magus on order flow and edge
In this episode, Magus shares his 11-year trading journey - from early tech stocks and silver to BitMEX-era crypto and full-time trading through the COVID crash. We dive deep into order flow, open interest, spot vs perp dynamics, and how market structure has evolved with ETFs and institutional flows. Magus explains his execution style, hedging philosophy, fixed sizing approach, and how professionalism, journaling, and emotional discipline shaped his edge. The conversation also explores DeFi as a “kingmaker” trade, reflections on missed opportunities like Hyperliquid, the current state of altcoins, and Bitcoin’s need to prove itself in a world where...
2026-02-12
1h 03
Insilico Terminal Podcast
"Don't blow up" - Merp on drawdowns, freedom, and surviving crypto
In this episode, Merp shares his journey from hospitality work during COVID to trading crypto full-time, navigating early bull-market luck, painful drawdowns, and the realities of maturing markets. We talk about buying dips, overthinking versus ignorance, working at a crypto fund through the FTX collapse, and why human dynamics often break funds. The conversation dives into perp DEXs vs options, airdrop farming, Hyperliquid, Extended, CT culture, founder behavior, and the social side of markets. We close with reflections on freedom, what it really means to “make it,” crypto’s future, and why the most important rule is simple: don’t blow u...
2026-02-05
58 min
Insilico Terminal Podcast
Why liquidity matters more than narrative - Fofty on macro and crypto
In this episode, Fofty shares his unconventional path into markets - from the euro crisis and the Wirecard collapse to crypto mining, ICOs, and eventually macro-driven trading across options, perps, and traditional markets. We explore how event-driven thinking, convexity, and seasonality shape his approach, why options offer a better way to express macro views, and how liquidity - not narratives - ultimately drives markets. The conversation dives deep into misunderstood macro dynamics, government liquidity hacks, Bitcoin’s struggle with credibility, CT culture, and why constant scamming undermines long-term adoption. We close with thoughts on the future of markets, Bitcoin’s ro...
2026-01-29
1h 08
AI Brief
EP 397 : Insilico Medicine Boosts AI in Pharma with MMAI Gym
Discover how Insilico Medicine's Science MMAI Gym is transforming Large Language Models into pharmaceutical-grade scientific engines, and get the latest on AI adoption in the workplace. Learn about groundbreaking research, including turning road traffic into a low-energy AI computer and a cow using tools with sophistication. Explore top AI tools like Clawdbot, Blink Agent Builder, and ChartGen AI to boost your productivity. Join the conversation and subscribe for more insights on AI and science. Don't miss out on the latest trends and innovations! Tools mentioned: Clawdbot, Blink Agent Builder, ChartGen AI, Noodle Seed, Fimo, Mastra, Tonkotsu, Interactpitch, OS Ninja.
2026-01-26
13 min
Insilico Terminal Podcast
Why doing nothing is often the best trade - DeltaXBT on patience and longevity
In this episode, DeltaXBT shares his journey from early Bitcoin exposure and getting wrecked in the 2017 altcoin cycle to becoming a disciplined, higher-timeframe trader focused on patience and simplicity. We talk about why he only trades a small basket of majors, how journaling and waiting for clean setups shaped his edge, and the hard lessons learned from losing over 90% of his net worth during the 2021 crash. Delta explains his approach to risk, leverage, boredom trading, and why doing nothing is often the best trade. The conversation also covers CT culture, trading psychology, transitioning toward TradFi markets, execution comfort with...
2026-01-22
58 min
Insilico Terminal Podcast
Why exchanges shouldn't work like casinos - World Markets on the future of on-chain trading
In this episode, we’re joined by Lucas and Hersch to dive deep into World Markets, a new fully on-chain “prime DEX” aiming to bring spot, perps, and lending together under a single, unified risk engine. Lucas explains the core insight behind building everything on-chain: atomic state, transparent risk, and capital efficiency that simply isn’t possible with hybrid or centralized architectures. We explore why traditional exchanges behave more like casinos than markets, how World Markets avoids ADLs through bilateral counterparty risk, and why circuit breakers, universal margin, and order-book–based lending matter. The conversation covers MegaETH vs Monad, listing ph...
2026-01-15
1h 03
Insilico Terminal Podcast
Why slow and boring wins - Mazino on scalping, risk, and staying profitable
In this episode, Mazino shares his journey from blowing up early spot bags in the 2017 era to becoming a disciplined, consistently profitable trader. We dive into how simplifying everything - cutting leverage, focusing on level-to-level price action, and journaling relentlessly - became the turning point. Mazino explains his evolution from swing trading into day trading and scalping, how he uses DOM and order flow as context rather than a crutch, and why patience and psychology matter more than theory. We also discuss building confluence, managing risk, compounding small edges, Hyperliquid and on-chain perps, journaling techniques, mentoring newer traders, and...
2026-01-08
59 min
The Patient Signal
Trump Urges GOP Flexibility on Abortion; Biobeat's Cuffless Monitor & Insilico-Servier AI Deal
In this episode, we delve into recent developments in politics, health care, and technology. Former President Donald Trump has called on Republicans to adopt a more flexible approach to abortion restrictions to secure a health care deal, emphasizing the need for compromise to achieve broader legislative goals. Meanwhile, Biobeat Technologies has raised $50 million to introduce its innovative cuffless blood pressure monitor to the U.S. market, despite skepticism from cardiovascular health bodies. Lastly, Insilico Medicine has partnered with Servier in a groundbreaking $888 million collaboration to leverage AI for drug discovery, highlighting the growing role of technology in the pharmaceutical...
2026-01-08
04 min
The Patient Signal
AI in Pharma: Insilico's Breakthrough, Hospital Tech Dilemma, and DEA's Telehealth Extension
In this episode, we explore the transformative role of AI in the pharmaceutical industry, highlighting Insilico Medicine's Rentosertib, the first AI-discovered drug poised for Phase 3 clinical trials. With AI investments projected to reach $16.49 billion by 2034, industry leaders like Eli Lilly are at the forefront, collaborating with tech giants to revolutionize drug discovery. Despite AI's promise, experts caution about its limitations in human trials. We also delve into the challenges hospitals face with new medical technology, likening it to a prisoner's dilemma. While robotic systems promise improved care, the costs and rapid tech advancements pose strategic dilemmas for...
2026-01-05
05 min
AI in Marketing
AI Revolution in Pharma, Journalism, and Tech: Insilico, Samsung, and Arrive Lead the Charge
In this episode, we explore the pharmaceutical industry's growing investment in AI for drug discovery, highlighted by Insilico Medicine's Rentosertib, the first AI-discovered drug entering Phase 3 trials. We also discuss the challenges of verifying AI-generated images, as seen in the scrutiny of a photo shared by President Trump. Looking ahead to CES 2026, expect innovations from Samsung and others, including advancements in RGB TV technology and foldable phones. Arrive AI Inc. is revolutionizing delivery with its smart mailbox system, showcased at CES. We examine the evolving review economy, where authenticity is challenged by strategic manipulation. HubSpot provides insights on improving...
2026-01-05
10 min
Tech News Daily
Samsung AI TVs Share Photos, LG Unveils Art Gallery TV, Roomba Gains HomeKit Amid Chaos, Insilico IPO Sparks HK Windfall, and more...
(0:10): Samsung's 2026 AI TVs to Feature Google Photos Integration for Enhanced Family Photo Sharing(1:25): LG Unveils Art-Infused Gallery TV at CES 2026: A Fusion of Technology and Aesthetics(3:16): Roomba's New Firmware Update Brings Apple HomeKit Compatibility Amid iRobot's Bankruptcy and Acquisition(5:09): Insilico Medicine's Landmark AI-Driven Biotech IPO Raises HK$2.277 Billion in Hong Kong(5:18): iPhone 16 Tops India's 2025 Smartphone Sales, Shifts Market Towards Premium DevicesTo subscribe visit https://www.brief.news.For more updates in your inbox each morning visit www.brief.news. Image credit: t2ONLINE
2025-12-31
08 min
Insilico Terminal Podcast
Inside Insilico's new execution engine - Denis on building for serious traders
In this episode, we trace the path from the early Insilico days to becoming CEO - from building exchange integrations as a developer to overseeing operations, legal, and team management. We discuss a shift in trading style toward spot positioning with perps used mainly for hedging, the engineering standards behind Insilico’s reliability, and why the team avoids AI-written code. The conversation covers major 2025 milestones, including a rebrand, podcast launch, a new Go + JavaScript execution engine that enables offline algos, and the evolution toward complex order baskets. We also explore prediction markets, Smart Hedge tooling, advanced order types like VW...
2025-12-25
1h 07
Insilico Terminal Podcast
How Satsdart rebuilt after getting zeroed in crypto
In this episode, we explore a trader’s journey from discovering Bitcoin during COVID to navigating the “up-only” phase of the bull market - and the hard reset after getting wiped in May 2021. He shares how rebuilding with strict Excel tracking restored discipline, lessons from Snowbank and Snowdog, and why publicly sharing trades shifted from community to extraction. We revisit the FTX collapse in Lisbon, discuss why most of his profits come from Bitcoin perps, and break down seasonality, ETH’s failed hedge narrative, and the current state of on-chain perp DEXs versus CEXs. The conversation closes with thoughts on today...
2025-12-18
1h 01
Insilico Terminal Podcast
"You don't need to trade everything" - Luckshury on Bitcoin, execution, and compounding
In this episode, we follow the journey from accounting into full-time trading, exploring the role of early luck versus building real systems. He shares how mentors like Tom Dante shaped a disciplined, career-oriented mindset and why specializing in Bitcoin gave him an edge - even as BTC’s structure and liquidity have fragmented since 2021. We dive into his philosophy of exploiting behavioral inefficiencies, managing drawdowns with data, and knowing when to step back. He demystifies order flow, explains his work on Exo Charts, and breaks down execution nuances like limit scaling and patient entries. The conversation closes with trading ps...
2025-12-11
1h 03
Insilico Terminal Podcast
"Trading is a professional sport" - TraderXO on what it really takes
In this episode, Trader XO breaks down his journey from banking and computer science into the 2017 bull run - and the painful lessons that followed after losing it all in 2018. He explains why 90% of traders fail, how embracing uncertainty is essential, and why risk management is ultimately a survival skill. We explore defining edge, expectancy, pattern recognition, and his 6-pillar trading framework. XO dives deep into psychology, recovering from tilt, building routines, dynamic risk sizing, and adding to winners. The discussion also covers strategy creation, volatility regimes, using LLMs for coding advantage, and journaling as a tool for longevity...
2025-12-05
1h 41
Insilico Terminal Podcast
Why most crypto traders never learn to sell - AvgReplyGuy on cycles and narratives
In this episode, we dive into the journey of a trader who entered crypto in 2016, lived through the 2017 alt mania, round-tripped early bags, and returned to the 2021 cycle far better prepared. He breaks down his current long-term swing approach, how he thinks about narratives, and why the Solana trade stood out. We talk tech vs narratives, tokenomics realism, and why Hyperliquid is one of the few “tech that actually matters.” The conversation explores learning to sell, avoiding CT sentiment traps, timeline curation, balancing work with trading, on-chain experiments, missed airdrops, public sales, and views on the current cycle - from...
2025-11-27
54 min
Insilico Terminal Podcast
Why patience became the edge - Abetrade on higher timeframes and evolving as a trader
In this episode, Adam - known as Abetrade —-shares his path from early binary options scams to trading German bonds, Bitcoin, and derivatives across markets. He talks about evolving from short-term order-flow scalping to longer-term swing and volatility strategies, using options and ETFs to trade mean reversion and risk premiums. Adam also dives into his work as Head of Trading at Breakout, recently acquired by Kraken, explaining prop-firm mechanics and risk management. The conversation closes with reflections on burnout, lifestyle balance, and why building sustainable habits matters more than chasing constant action.Insilico Terminal Podcast Episode 11 - Ab...
2025-11-20
1h 02
Insilico Terminal Podcast
Why simple systems beat overthinking - Scott Phillips on crypto edge
In this episode, Scott shares his journey from a TradFi background to finding success in crypto’s early DeFi days. He breaks down momentum effects, on-chain inefficiencies, and how simple systems often outperform over-optimized ones. The discussion covers mid-frequency quant trading, partnering with market makers, and the psychology of trend following. Scott also opens up about burnout, mental health, and his personal story of redemption - ending with reflections on the future of systematic trading, vault design, and finding peace beyond success.Insilico Terminal Podcast Episode 10 - Scott Phillips00:00 Intro, Scott’s background in TradFi, pivo...
2025-11-13
1h 16
Insilico Terminal Podcast
From DOM scalper to algo fund manager - Nikalgo on building real trading skill
In this episode, Nick shares his journey from discovering markets to mastering DOM scalping and developing a unique order book–driven style. He dives into breakout and knife-catching setups, lessons from the Russian scalping scene, and his transition into algorithmic trading with Spreadfighter. The conversation explores building an algo fund through volatile markets, adapting as edges decay, managing risk, and lessons from major drawdowns - ending with insights on protecting capital, holding winners, and embracing positive tails.Insilico Terminal Podcast Episode 9 - Nikalgo 00:00 Intro, Nick’s background, early exposure to markets and discovering crypto06...
2025-11-06
1h 09
Insilico Terminal Podcast
"You have to adapt" - Ponzi Maxi on airdrops, perps, and crypto's new meta
In this episode, Ponzi shares his path from early on-chain trading to joining Spartan Group, reflecting on big wins, losses, and emotional lessons along the way. He talks about the Hyperliquid airdrop era, shifting from altcoins to perps, and developing structured strategies in a team environment. The conversation covers trading psychology, DEX competition, public sales, and the evolving airdrop meta - ending with insights on adaptability, letting go of old bags, and staying sharp in changing markets.Insilico Terminal Podcast Episode 8 - Ponzi Maxi 00:00:00 Intro, Ponzi’s background, getting into crypto and early trading years
2025-10-30
1h 10
Insilico Terminal Podcast
Building a self-custody exchange - Ruslan on the vision behind Extended
In this episode, Ruslan, founder of Extended, shares his journey from Revolut to building a fully self-custodial exchange. He explains the vision behind Extended’s unified margin and multi-asset collateral system, the choice to build on Starknet, and the challenges of trustless architecture. The discussion dives into liquidation logic, exchange stability during volatile markets, and what sets Extended apart - closing with thoughts on sustainable growth, token plans, and the future of decentralized trading.Insilico Terminal Podcast Episode 7 - Extended Founder Ruslan00:00 Intro, Ruslan’s background, founding Extended, and vision for a self-custody exchange06...
2025-10-23
59 min
Insilico Terminal Podcast
Why Heart stopped shorting - and what it taught him about trading psychology
In this episode, Heart shares his journey from the early DeFi days to becoming a disciplined trend trader. He talks about the lessons from his first bear market, how trading psychology reshaped his approach, and why he stopped shorting. The discussion covers trend following, coin rotation, using CT as signal, and the role of community, journaling, and personal growth -ending with insights on managing size, staying sharp, and building long-term freedom through trading.Insilico Terminal Podcast Episode 6 - Heart00:00:00 Intro, Heart’s background, getting into crypto and the early DeFi boom00:04:38 From on-chain de...
2025-10-16
1h 12
Insilico Terminal Podcast
Positioning vs prediction - VNTGPRN on macro edge in crypto
In this episode, V discusses developing as a trader through the 2021–22 bear market and how a macro framework shapes his approach. He breaks down positioning vs prediction, interest rate differentials, and carry trades, while exploring how macro conviction translates into intraday execution. The conversation covers narratives, data, Fed policy, crypto rotations, and possible next bear market scenarios — ending with insights on building edge, balancing discretion and quant, and leveraging the right tools.Insilico Terminal Podcast Episode 5 - VNTGPRN00:00:00 Intro, V’s background, starting to trade during the 2021–22 bear market00:05:09 Macro traders, positioning vs predicti...
2025-10-09
1h 19
Insilico Terminal Podcast
How DocXBT built a trader's mindset - from medicine to markets
In this episode, Doc shares his journey from medicine to trading, how discipline from tennis shaped his approach, and the evolution of his strategies from trend trading to intraday mean reversion. He dives into mentors, CT culture, execution with Insilico Terminal, on-chain opportunities, work-life balance, and his long-term outlook on markets and trading as both a craft and a lifestyle.Insliico Terminal Podcast Episode 4 - DocXBT00:00:00 Intro, Doc’s path from medicine to trading, early obsession during the bear market00:13:21 Tennis mindset applied to trading, discipline, handling losses and setbacks00:26:36 Transition fr...
2025-10-02
1h 11
TD Cowen Insights
Unlocking AI KPIs With Insilico CEO Alex Zhavoronkov
Recorded on 06/24/25TD Cowen's Machine Medicine: AI & Health Care podcast series takes on the cross-sector revolution in artificial intelligence and breaks it down one piece at a time. We highlight some of the biggest misconceptions about how AI is and can be used in different health care settings and aim to contextualize the latest and most impactful developments in a field defined by rapid innovation. In this episode, TD Cowen's health care analyst Brendan Smith hosts Alex Zhavoronkov, chief executive officer and founder of Insilico Medicine, to explore how Insilico is helping define some of the most...
2025-09-30
42 min
Insilico Terminal Podcast
From getting rekt to trading with precision - Alucard on HFT & DEXs
Alucard shares his journey from early mistakes and risk lessons through bull & bear markets, into HFT, orderflow, and mean reversion strategies—plus insights on DEX growth, delta-neutral yields, and advice for newcomers.Insilico Terminal Podcast Episode 3 - Alucard 00:00 Background, getting into crypto, early mistakes and lessons07:00 Bull & Bear experiences, learning risk management, Luna, FTX10:30 Moving into HFT, latency/arb focus, division of engineering vs strategy 18:06 Trading strategies, mean reversion, orderflow 23:00 When scalps become swings; liquidation lines, trench sizing; avoid true bagholding27:00 From years lurking to posti...
2025-09-25
1h 00
Flot.bio x Philip Hemme
Alex Zhavoronkov, Insilico Medicine | AI Drug Development, Longevity | E39
We chat about longevity with Alex Zhavoronkov, CEO and founder of the artificial intelligence (AI) specialist Insilico Medicine.Born in Latvia, Alex founded Insilico in 2014, with the company raising a huge $110M Series E round this year.Alex gives us a tour of Insilico’s sprawling pipeline, a blunt rundown of the competitive landscape in AI drug development, and explains how Insilico is navigating the huge challenges faced by longevity-focused startups.⭐️ ABOUT THE SPEAKERAlex founded Insilico in 2014 after serving in senior roles at ATI Technologies, NeuroGNeuroinformatics, and the Bi...
2025-09-24
58 min
Insilico Terminal Podcast
How Marusha went from bull run luck to real trading skill
This episode follows Marusha’s journey from gaming into crypto, exploring her early trading wins, burnout, and return with a deeper focus on options and algorithmic strategies. We dive into CT culture, on-chain perps vs. options, Hyperliquid, pump.fun, and the love/hate relationship traders have with the market. Insilico Terminal Podcast Episode 2 - Marusha 0:00 Marusha background, move into crypto, gaming connection, first mentor 06:56 Early trading experiences, bullrun luck, burnout, taking a break to study options and algo trading 12:31 Joining Discord & Crypto Twitter, learning from criticism, evolution of CT culture and knowle...
2025-09-18
1h 02
Insilico Terminal Podcast
Insilico Terminal Podcast Episode 2 - Flood
In this episode we sit down with Flood to trace his crypto journey. From early gaming days to navigating major setbacks, he shares insights on developing trading discipline, building successful products, and maintaining perspective during both wins and losses. The discussion covers community building in crypto, the evolution of trading platforms, and practical philosophy on risk-taking and capital allocation. Raw perspectives on what it takes to succeed long-term in volatile markets and life lessons learned along the way.0:00 Introduction, path into trading, gaming & poker lessons, life as a trade 8:10 Major downswings, FTX collapse, handling setbacks ...
2025-09-08
1h 17
Insilico Terminal Podcast
How FTX and the bear market made Pierre Crypto a better trader
In this episode with Pierre Crypto we cover getting started in crypto, lessons from FTX, building trading strategies and systems, and the mindset needed to stay consistent. We also discuss lifestyle changes, the evolution of Crypto Twitter, execution in trading, and wrap up with thoughts on Hyperliquid, airdrops, and the future of CEX/DEX.Insilico Terminal Podcast Episode 1 - Pierre Crypto 0:00 Getting started in crypto and trading, gaming history and transferable skills, taking accountability15:30 Learnings and being humbled, FTX21:40 Development of trading strategy, mental aspects, system building, trend trading35:50 D...
2025-08-18
1h 20
BTBA presents: 生技來一刻
S5 EP11|AI 藥物開發系列|Insilico Medicine ft. 林彥竹博士
人工智慧(AI)如何改變藥物開發?藥物開發從臨床前研究到臨床試驗,通常需要超過十年時間和數十億美元的投資,卻仍有高達九成的藥物在臨床試驗中失敗。這些挑戰,現在 AI 正在各種方面掀起革命。在這系列節目中,我們將探討 AI 在藥物開發領域中的應用,並介紹在這個快速發展的領域中工作的專家。 本集為《AI 藥物開發系列》的第二集。在本集節目中,我們特別邀請到了陽明交大的兼任助理教授林彥竹,他同時也是英科智能 Insilico Medicine 台灣區的前 CEO*。他將分享他從臺大藥學院畢業後,如何跨足至瑞士聯邦理工學院,並進入英科智能深耕 AI 藥物開發的豐富經歷,以及他對於 AI 在生醫領域未來發展的看法。 此外,我們也探討英科智能的平台如何加速藥物篩選的過程,從而大幅縮短從實驗室到臨床的時間。希望大家將能更清楚地了解 AI 如何改變傳統藥物研發流程,以及這場科技革命如何影響生醫領域的未來。 *註: 講者受訪時仍任職於英科智能 🧑💼 講者 | 林彥竹 Jimmy Yen-Chu Lin:https://www.linkedin.com/in/jimmy-yen-chu-lin-74785199/ 🎤 主持人 | 紀威佑 Wei-Yu Chi:https://www.linkedin.com/in/wychi/ 🎤 主持人 | 吳畇芸 Yun-Yun (Sonja) Wu:https://www.linkedin.com/in/yun-yun-wu-3b0303106/ 🧑💻 後製 | 吳畇芸 Yun-Yun (Sonja) Wu:https://www.linkedin.com/in/yun-yun-wu-3b0303106/ 生技來一刻 Facebook 專頁:https://www.facebook.com/moment.in.biotech BTBA Facebook 專頁:https://www.facebook.com/btbatw BTBA Podcast 網站:http://btbatw.org/podcast 《生技來一刻》感謝國科會與駐波士頓辦事處科技組贊助我們製作節目。我們也歡迎聽眾的小額捐款,您的支持能幫助我們製作更優質的節目。https://www.paypal.com/US/fundraiser/charity/2101877 🎧 過去相關訪問: AI 藥物開發系列|導論 https://tmrbiotechmoments.podbean.com/e/aidd_intro/ 精準醫療與藥物開發全面啟動 ft. 人工智慧絕地武士林清詠 https://tmrbiotechmoments.podbean.com/e/ft-ching-yung-lin/ 藥廠計算生物學家 ft. 周文奇博士、林書弘博士 https://tmrbiotechmoments.podbean.com/e/wen_chi_chou_shu_hong_lin/ 時間軸 講者自我介紹與經歷 (02:18) CADD和AIDD的不同(14:10) 在 Insilico Medicine 擔任 CEO 的經驗 (26:37) 公司如何應用 AI 藥物開發 (37:00) AI 的侷限、挑戰與展望 (1:02:44) 給年輕人的建議 (1:13:19)
2025-03-02
1h 23
Aladdin’s Adventure
Episode15:Insilico Medicine, The 1st AIDD Company Delivered
End-to-End AI and Robotics Platform: Insilico has developed a commercially available, end-to-end platform that integrates generative AI and robotics to enhance the quality and productivity of pharmaceutical research. This platform includes:PandaOmics: A tool for aging research, disease modeling, and novel target discovery and prioritization.Generative Chemistry and Generative Biologics: Engines for designing and optimizing novel biomolecules, including on-the-fly optimization, kinase selectivity analysis, and relative binding free energy prediction.Alchemistry and ADMET Profiling: Platforms for predicting chemical properties, synthesis routes, and assessing the absorption, distribution, metabolism, excretion, and toxicity of drug candidates.
2024-11-19
18 min
Slice of Technology
#10 - Alex Zhavoronkov, Founder & CEO at Insilico Medicine
Join us on this week's episode of the Slice of Technology AI podcast, hosted by Jared S. Taylor! Our Guest: Alex Zhavoronkov, Founder & CEO at Insilico Medicine.What you’ll get out of this episode:Insilico Medicine's AI-Driven Approach: Using deep learning for drug discovery, target identification, and disease modeling.Focus on Longevity: Alex Zhavoronkov’s mission to extend healthy human lifespan through advanced AI technologies.Life Models & Beyond: Development of life models using multi-modal transformers to understand aging and biology across species.Future of Biotech: Exploration of novel materials for sustainability and quantum computing's pote...
2024-09-30
24 min
The Daily Snapshot - A.I.
A.I. drug discovery platform Insilico Medicine announces $255 million in Series C funding
Insilico Medicine, a drug discovery platform that leverages artificial intelligence, has raised $255 million in Series C funding, marking a significant financial boost following a recent breakthrough demonstrating its platform's capability to innovate in drug development.
2024-03-20
11 min
One North Stories
014 Hello Tomorrow AP 2023 Preview with Insilico Medicine and String Bio
This is One North Stories, an A*START CENTRAL PodcastHello Tomorrow Asia Pacific Summit is happening on 27th September 2023 at the National Gallery in Singapore. Tune in for a brief preview of the Summit itself, the investor day happening on 26th September 2023 plus interview with two participating tech companies: Insilico Medicine and Spring Bio.Insilico Medicine is an AI company, a software company, a drug discovery company and now a clinical stage biotech company, revolutionizing drug discovery and testing through generative AI.Spring Bio is redefining manufacturing and enabling resilient food systems...
2023-08-31
37 min
AWS Health Innovation Podcast
#56, Alex Zhavoronkov and the GenAI Revolution in Drug Discovery at Insilico Medicine
On the latest episode of the AWS Health Innovation Podcast, Dr. Yin He, Principal Business Development, Healthcare & Life Sciences Startups, welcomes Alex Zhavoronkov, the CEO of Insilico Medicine, to the show for a fascinating conversation about their transformative work at the intersection of AI & BioTech. Insilico Medicine is an end-to-end generative AI-driven biotech company. They harness the capabilities of their proprietary Pharma.AI platform to accelerate drug discovery & development. The conversation goes into detail about how Insilico uniquely combines AI and genomics to bridge computation and biology, enabling them to help global pharmaceutical companies accelerate their drug...
2023-07-12
46 min
Life Science Success
Alex Zhavoronkov - CEO Insilico Medicine
Send us Fan MailIn this episode of Life Science Success my Guest is Alex Zhavoronkov. Alex is the CEO Insilico Medicine an AI-powered drug discovery company. Insilico Medicine has progressed three internally-derived assets into human clinical trials. Insilico Medicine has discovered over 30 other programs in different stages. Insilico Medicine incorporates three engines in their platform: biology, chemistry, and clinical. They generate normal molecules with desired properties using 42 generative engines. They have a system that predicts clinical trials outcomes. Insilico Medicine’s main strategy is partnering with pharma companies at the preclinical candidate stage. They value pat...
2023-06-10
24 min
Under The Radar
Under the Radar: The role of Generative AI on drug discovery – Insilico Medicine’s CEO on positioning against large pharma players; Global market for AI enabled drug discovery to grow at a CAGR of 26.3%; Collaboration with Sanofi worth up to US$1.2b
From content writing, to providing human-like responses in chatbots, and to even coding. Generative AI has made its potential known to the world with the introduction of ChatGPT. But besides, did you know that generative AI can be used in the process of drug discovery as well? Today we speak with Insilico Medicine, a clinical stage AI driven drug discovery company that is delivering breakthrough solutions to discover and develop medicines in areas such as cancer, immunity and ageing. The company was selected by NVIDIA as one of the top 5 AI companies for it...
2023-05-02
28 min
The Harry Glorikian Show
Insilico Brings Generative AI to Drug Development and Discovery
It may feel like generative AI technology suddenly burst onto the scene over the last year or two, with the appearance of text-to-image models like Dall-E and Stable Diffusion, or chatbots like ChatGPT that can churn out astonishingly convincing text thanks to the power of large language models. But in fact, the real work on generative AI has been happening in the background, in small increments, for many years. One demonstration of that comes from Insilico Medicine, where Harry's guest this week, Alex Zhavoronkov, is the co-CEO. Since at least 2016, Zhavoronkov has been publishing papers about the p...
2023-03-28
1h 29
AI Business Podcast
Insilico Medicine’s Head of AI Platforms on Revolutionizing Drug Discovery
Petrina Kamya, head of AI platforms at Insilico Medicine, talks to Andrew Brosnan, principal analyst in AI and Applied Intelligence at Omdia, to take a deep dive into the intricacies of AI-powered drug discovery.
2022-12-14
29 min
AI News
#2127 OpenAI / Insilico Medicine / XPRIZE / Nvidia Canvas / Virtual Student
David Silver, head of the Reinforcement Learning research group at DeepMind, is awarded the honorary ranking of "Ninth Dan" for AlphaGo. https://www.cnbc.com/2021/06/18/computer-scientists-ask-if-deepmind-can-ever-make-ai-human-like.html Insilico Medicine, an AI-based drug development and discovery platform, announced Tuesday Series C funding of $ 255 million. https://techcrunch.com/2021/06/22/a-i-drug-discovery-platform-insilico-medicine-announces-255-million-in-series-c-funding/?guccounter=1 XPRIZE, the world's leading provider of incentive competitions to solve the world's great challenges, and IBM Watson, IBM's AI technology for business, today announced the grand prize winner of the $ 5 million IBM Watson AI XPRIZE Challenge. " https://www.businesswire.com...
2021-07-05
04 min
AI News auf Deutsch
#2127 OpenAI / Insilico Medicine / XPRIZE / Nvidia Canvas / Virtual Student
David Silver, Leiter der Forschungsgruppe Reinforcement Learning bei DeepMind, wird für AlphaGo mit dem Ehren-Rangliste "Neunter Dan" ausgezeichnet. https://www.cnbc.com/2021/06/18/computer-scientists-ask-if-deepmind-can-ever-make-ai-human-like.html Insilico Medicine, eine KI-basierte Plattform für die Entwicklung und Entdeckung von Medikamenten, kündigte am Dienstag eine Serie-C-Finanzierung in Höhe von 255 Millionen US-Dollar an. https://techcrunch.com/2021/06/22/a-i-drug-discovery-platform-insilico-medicine-announces-255-million-in-series-c-funding/?guccounter=1 XPRIZE, der weltweit führende Anbieter von Incentive-Wettbewerben zur Lösung der großen Herausforderungen der Menschheit, und IBM Watson, IBMs KI-Technologie für Unternehmen https://www.businesswire.com/new s/home/20210623005848/en/Grand...
2021-07-05
05 min
AI News po polsku
#2127 OpenAI / Insilico Medicine / XPRIZE / Nvidia Canvas / Virtual Student
Podcast jest dostępny także w formie newslettera: https://ainewsletter.integratedaisolutions.com/ David Silver, lider grupy badawczej ds. https://www.cnbc.com/2021/06/18/computer-scientists-ask-if-deepmind-can-ever-make-ai-human-like.html Insilico Medicine, oparta na sztucznej inteligencji platforma do opracowywania i odkrywania leków, ogłosiła we wtorek 255 milionów dolarów finansowania serii C. https://techcrunch.com/2021/06/22/a-i-drug-discovery-platform-insilico-medicine-announces-255-million-in-series-c-funding/?guccounter=1 XPRIZE, światowy lider w projektowaniu i prowadzeniu konkursów motywacyjnych mających na celu rozwiązywanie wielkich wyzwań ludzkości, oraz IBM Watson, technologia AI IBM dla biznesu, https://www.businesswire.com/news/home...
2021-07-05
05 min
TomorrowScale Podcast
Generating Discoveries in Days - InSilico Medicine
Drug discovery is changing. Deep generative models, as being pioneered by our guest Dr. Alex Zhavoronkov, founder and CEO of InSilico Medicine, are able to generate entirely new molecules and even, as we’ll hear, can discover new targets altogether. Within days. This fall, InSilico and collaborators published an application of their generative reinforcement learning (GENTRL) to generate tens of thousands of novel compounds, synthesized only the 6 best, and identified a selective and nanomolar-potent candidate among them. We discuss deep generative drug discovery models, promise and criticism on these new methodologies, and dive into new research from th...
2020-02-06
37 min
Level Up! Your Business, Life & Mind
10 - INTERVIEW WITH QUENTIN VANHAELEN - Director of the Virtual Human Project at Insilico
Quentin Vanhaelen is the Director of the Virtual Human Project at Insilico Medicine, a startup that has achieved a Series B funding for about $37 Million USD. They are using artificial intelligence and deep learning to identify bio markers in the human DNA to help aging research and medicine discovery that can help us extend longevity in the human race. Quentin has a Bachelor's & Masters degree in Physical Sciences and a PhD in Philosophy and Theoretical Physics, he's originally from Belgium he joins us today from Moscow to discuss the theories of aging, artificial intelligence a...
2020-01-29
1h 06
Faces of Digital Health
F036 How is AI decoding aging? (Alex Zhavoronkov, Insilico Medicine)
Longevity, eternal youth or even immortality have been an aspiration in religion and culture throughout history. Today, people adopt all sorts of approaches to increase their wellbeing, delay aging and avoid diseases. Efforts are increasingly quantified with sensors, wearables, or even biohacking - interventions to influence body biology. The new hope for advancements in longevity is seen in artificial intelligence, which is becoming increasingly powerful. Alex Zhavoronkov has been researching the use of AI in aging for years. He is the CEO of Insilico Medicine, a Baltimore-based leader in the next-generation artificial intelligence technologies for drug discovery and aging biomarkers disco...
2019-05-03
50 min
The Remarkable SaaS Podcast
#13 - Alex Zhavoronkov, CEO of Insilico Medicine - On using AI to add quality years to human life
My guest on the podcast this week is Alex Zhavoronkov, CEO of Insilico MedicineOn a day-to-day basis, Alex is the CEO of Insilico Medicine (www.insilico.com), which is focused exclusively on developing and applying deep learning methods to drug discovery. It’s probably the largest next-gen AI and bioinformatics company in the world, focusing exclusively on aging and age-related diseases.Alex is also the director of the Biogerontology Research Foundation and the founder of the International Aging Research Portfolio. He heads the laboratory of regenerative medicine at the Center for Pediatric Hematology-Oncology and Im...
2018-04-23
29 min